ArticleOncology letters2019
Resveratrol integrates metabolic and growth effects in PC3 prostate cancer cells-involvement of prolyl hydroxylase and hypoxia inducible factor-1.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Plant-Derived Polyphenols in Cancer Therapy: Bridging Molecular Mechanisms and Bioavailability Toward Clinical Translation.Pharmaceutics · 2026Review
- In vitro cytotoxicity of medicinal plants used in prostate cancer management in Africa: a systematic review.Tropical medicine and health · 2026Review
- The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.Biomedicines · 2024Review
- Bibliometric and visualized analysis of resveratrol in anticancer investigations.Food science & nutrition · 2024Review
- The Growth Inhibitory Effect of Resveratrol and Gallic Acid on Prostate Cancer Cell Lines through the Alteration of Oxidative Stress Balance: The Interplay betweenAnti-cancer agents in medicinal chemistry · 2024Article
- Multidimensional biological activities of resveratrol and its prospects and challenges in the health field.Frontiers in nutrition · 2024Review
- Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions.Antioxidants (Basel, Switzerland) · 2023Review
- Resveratrol againstTropical medicine and infectious disease · 2023Article
- Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer.Cancers · 2023Review
- Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment.Pflugers Archiv : European journal of physiology · 2022Review
- Metastasis-associated protein 1-mediated antitumor and anticancer activity of dietary stilbenes for prostate cancer chemoprevention and therapy.Seminars in cancer biology · 2022Review
- Targeting Mitochondrial OXPHOS and Their Regulatory Signals in Prostate Cancers.International journal of molecular sciences · 2021Review
- Bioassay-Guided Identification of the Antiproliferative Compounds ofMolecules (Basel, Switzerland) · 2021Article
- Review
- Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review.Frontiers in nutrition · 2021Review
- Natural products and phytochemical nanoformulations targeting mitochondria in oncotherapy: an updated review on resveratrol.Bioscience reports · 2020Review
- Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets.Cells · 2020Review
- Oxygen and Glucose Levels in Cell Culture Media Determine Resveratrol's Effects on Growth, Hydrogen Peroxide Production, and Mitochondrial Dynamics.Antioxidants (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol (RES) is a polyphenol produced by certain plant species that has been well studied due to its ability to slow the growth of cancer cells. In numerous cell types and tissues, RES has been demonstrated to promote mitochondrial biogenesis, fusion, and oxidative phosphorylation. The present study investigated the interaction between RES's effects on growth and metabolism in PC3 prostate cancer cells, and demonstrated that RES-mediated growth inhibition is only observed under conditions in which a metabolic shift from glucose fermentation to mitochondrial respiration can occur. When this shift was prevented by growing cells in galactose medium or by pharmacologically inhibiting prolyl hydroxylase (PHD) in order to stabilize hypoxia inducible factor-1α, RES did not effect mitochondrial fusion, biogenesis, respiration or cell growth. Similar results were observed in PC3 cells expressing a mutant HIF-1α lacking the prolines that are hydroxylated by PHD to promote its degradation. Thus, RES appears to slow PC3 cell growth by interfering with glucose fermentation and promoting respiration. Consistent with this, RES was observed to be particularly effective at inhibiting PC3 cell growth under hypoxic conditions that precluded increased reliance on oxidative phosphorylation. These observations are important in understanding how RES may affect cancer cell growth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.